Try
Immunovant Inc. Common Stock
IMVTUnited States
30 filed reports · 312 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
30 reports · Mar 2019 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 23 | 2,327 | Mar 2019 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 7 | 2,003 | Mar 2020 to Mar 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2027 Q1 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 216 | Open |
| FY2026 | 10-K | Mar 31, 2026 | May 20, 2026 | 536 | Open |
| FY2026 Q3 | 10-Q | Dec 31, 2025 | Feb 6, 2026 | 165 | Open |
| FY2026 Q2 | 10-Q | Sep 30, 2025 | Nov 10, 2025 | 126 | Open |
| FY2026 Q1 | 10-Q | Jun 30, 2025 | Aug 11, 2025 | 93 | Open |
| FY2025 | 10-K | Mar 31, 2025 | May 29, 2025 | 230 | Open |
| FY2025 Q3 | 10-Q | Dec 31, 2024 | Feb 6, 2025 | 102 | Open |
| FY2025 Q2 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 81 | Open |
| FY2025 Q1 | 10-Q | Jun 30, 2024 | Aug 6, 2024 | 85 | Open |
| FY2024 | 10-K | Mar 31, 2024 | May 29, 2024 | 159 | Open |
| FY2024 Q3 | 10-Q | Dec 31, 2023 | Feb 12, 2024 | 98 | Open |
| FY2024 Q2 | 10-Q | Sep 30, 2023 | Nov 9, 2023 | 82 | Open |
Financial data
312 concepts · 4,330 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial300 concepts · 4,192 facts · Dec 2017 to Aug 2026
- Net income loss42 · Jun 2018 to Jun 2026
- Stockholders equity (US GAAP)42 · Jun 2018 to Jun 2026
- Common stock shares authorized40 · Dec 2018 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax40 · Jun 2018 to Jun 2026
- Additional paid in capital39 · Dec 2018 to Jun 2026
- Allocated share based compensation expense39 · Dec 2018 to Jun 2026
- Assets39 · Dec 2018 to Jun 2026
- Assets current39 · Dec 2018 to Jun 2026
- Cash and cash equivalents at carrying value39 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents39 · Dec 2018 to Jun 2026
- Common stock shares issued39 · Dec 2018 to Jun 2026
- Common stock shares outstanding39 · Dec 2018 to Jun 2026
- Common stock value39 · Dec 2018 to Jun 2026
- Comprehensive income net of tax39 · Dec 2018 to Jun 2026
- General and administrative expense (US GAAP)39 · Dec 2018 to Jun 2026
- Income tax expense benefit39 · Dec 2018 to Jun 2026
- Liabilities39 · Dec 2018 to Jun 2026
- Liabilities and stockholders equity39 · Dec 2018 to Jun 2026
- Operating expenses (US GAAP)39 · Dec 2018 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent39 · Dec 2018 to Jun 2026
- Other nonoperating income expense39 · Dec 2018 to Jun 2026
- Retained earnings accumulated deficit39 · Dec 2018 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value38 · Sep 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect38 · Mar 2019 to Jun 2026
Geography6 concepts · 69 facts · Mar 2019 to Mar 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest26 · Mar 2021 to Mar 2026
- Income loss from continuing operations before income taxes minority interest and income loss from equity method investments15 · Mar 2019 to Mar 2021
- Current state and local tax expense benefit9 · Mar 2019 to Mar 2026
- Current federal tax expense benefit8 · Mar 2019 to Mar 2026
- Effective income tax rate continuing operations8 · Mar 2019 to Mar 2026
- Current foreign tax expense benefit3 · Mar 2019 to Mar 2021
Segment6 concepts · 69 facts · Mar 2023 to Jun 2026
- Interest income expense nonoperating net13 · Mar 2023 to Jun 2026
- Labor and related expense13 · Mar 2023 to Jun 2026
- Net income loss13 · Mar 2023 to Jun 2026
- Other general and administrative expense13 · Mar 2023 to Jun 2026
- Segment reporting other item amount13 · Mar 2023 to Jun 2026
- Research and development asset acquired other than through business combination written off4 · Mar 2023 to Mar 2026
Segments
138 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement geographical6 members · 69 facts
- US31 · Mar 2019 to Mar 2026
- BM10 · Mar 2019 to Mar 2026
- CH9 · Mar 2019 to Mar 2026
- GB9 · Mar 2019 to Mar 2026
- All Other Countries8 · Mar 2019 to Mar 2022
- State And Local Jurisdiction2 · Mar 2019 to Mar 2020
Statement business segments1 member · 69 facts
- Reportable69 · Mar 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary74 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary179 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes25 claims from 1 reports · Mar 2026
- Risk factors158 risks from 2 annual reports · 2025 to 2026
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2027 Q1Aug 6, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.